ramucirumab,pembrolizumab
eli lilly,merck
['s1800a', 'sclc', 'nsclc', 'ramucirumab', 'pembrolizumab']
metastatic nsclc #asco2022 s1800a - phase ii rct - pembrolizumab + ramucirumab vs soc px: pd with previous io + platinum doublet primary end-point: os 1/4 
Heme Onc Chief Fellow @ University of New Mexico/ Thoracic and Head and Neck Oncology /Latino ????????